e-learning resources

ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Mesothelioma and malignant pleural disease

Poster Discussion
Chairs: P. Astoul (Marseille, France), N. Rahman (Oxford, United Kingdom)

Download all media

Download all media

LSC - 2017 - Targeting CD98hc: a key mediator of tumour and microenvironmental crosstalk in malignant mesothelioma C. Rooney (GLASGOW, United Kingdom)
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) V. Pinelli (Brescia, Italy)
Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma M. Christofidou-Solomidou (Philadelphia, United States of America)
Exhaled breath analysis allows exclusive screening for malignant pleural mesothelioma. K. Lamote (Wilrijk, Belgium)
Pleural fluid DNA integrity index as a diagnostic marker of malignant pleural effusion M. Yousif (Menoufia Gavornorate, Egypt)
Utility of conjoined EBUS-TBNA, ROSE (rapid-on site evaluation) and flow cytometry in diagnosis of lymphoma M. Medenica (Manchester, United Kingdom)
Comparison of multiple serum and pleural fluid biomarkers for the diagnosis of Malignant Pleural Mesothelioma D. Neville (Portsmouth, United Kingdom)
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) D. De Fonseka (Bristol, United Kingdom)
Effects of Cisplatin and Pemetrexed on the cell viability and cell adhesion of benign mesothelial and mesothelioma cells. O. Kotsiou (Larisa, Greece)
Investigation of CD14 with toll like receptors expression in pleural effusion for detection of thoracic disorders E. Mortaz (Tehran, Islamic Republic of Iran)
Retrospective analysis of survival time in malignant pleural effusion requiring IPC insertion R. Asciak (Oxford, United Kingdom)
Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles. G. Stella (Pavia, Italy)
Trends in malignant pleural mesothelioma in Eskisehir province of Turkey from January 1990 to December 2016 S. Metintas (Eskisehir, Turkey)
Prognostic characteristics of malignant pleural mesothelioma M. Metintas (Eskisehir, Turkey)
A retrospective 1 year analysis of our newly founded Pleural Service J. Gurung (Swansea, United Kingdom)
Does a posteriorly or interlobularly positioned chest tube really affect the success rate of pleurodesis? T. Takemura (Amagasaki, Hyogo, Japan)
Outcomes of an elective day case tunnelled indwelling pleural catheter service Y. Madani (London, United Kingdom)
Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients C. Chung (Taipei, Taiwan)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.